CLSD Clearside Biomedical Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLSD

Price (delayed)

$1.03

Market cap

$64.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$77.28M

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside's proprietary SCS ...

Highlights
The company's gross profit has shrunk by 94% YoY but it rose by 38% QoQ
The revenue has plunged by 92% YoY but it has grown by 37% from the previous quarter
CLSD's equity has dropped by 169% year-on-year and by 158% since the previous quarter
CLSD's quick ratio has plunged by 51% YoY and by 24% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://clearsidebio.com
Peers: OMGA

Key stats

What are the main financial stats of CLSD
Market
Shares outstanding
62.41M
Market cap
$64.28M
Enterprise value
$77.28M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
28.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.95
Earnings
Revenue
$2.21M
EBIT
-$37.32M
EBITDA
-$37.25M
Free cash flow
-$25.99M
Per share
EPS
-$0.61
Free cash flow per share
-$0.42
Book value per share
-$0.21
Revenue per share
$0.04
TBVPS
$0.56
Balance sheet
Total assets
$34.42M
Total liabilities
$47.27M
Debt
$41.8M
Equity
-$12.85M
Working capital
$24.98M
Liquidity
Debt to equity
-3.25
Current ratio
5.28
Quick ratio
5.09
Net debt/EBITDA
-0.35
Margins
EBITDA margin
-1,684.6%
Gross margin
74.7%
Net margin
-1,687.7%
Operating margin
-1,356.8%
Efficiency
Return on assets
-88%
Return on equity
N/A
Return on invested capital
-100.9%
Return on capital employed
-130.5%
Return on sales
-1,687.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CLSD stock price

How has the Clearside Biomedical stock price performed over time
Intraday
1.98%
1 week
1.98%
1 month
34.99%
1 year
-12.71%
YTD
-8.04%
QTD
18.4%

Financial performance

How have Clearside Biomedical's revenue and profit performed over time
Revenue
$2.21M
Gross profit
$1.65M
Operating income
-$30M
Net income
-$37.32M
Gross margin
74.7%
Net margin
-1,687.7%
The company's gross profit has shrunk by 94% YoY but it rose by 38% QoQ
The revenue has plunged by 92% YoY but it has grown by 37% from the previous quarter
The operating margin is up by 26% from the previous quarter
CLSD's gross margin is down by 25% YoY

Growth

What is Clearside Biomedical's growth rate over time

Valuation

What is Clearside Biomedical stock price valuation
P/E
N/A
P/B
N/A
P/S
28.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
34.95
The EPS has declined by 3.4% since the previous quarter
CLSD's equity has dropped by 169% year-on-year and by 158% since the previous quarter
The revenue has plunged by 92% YoY but it has grown by 37% from the previous quarter
The P/S is 78% below the 5-year quarterly average of 130.7 and 37% below the last 4 quarters average of 45.6

Efficiency

How efficient is Clearside Biomedical business performance
Clearside Biomedical's return on invested capital has shrunk by 79% YoY but it has increased by 4.6% QoQ
The return on sales has grown by 24% since the previous quarter
The company's return on assets fell by 17% QoQ

Dividends

What is CLSD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLSD.

Financial health

How did Clearside Biomedical financials performed over time
The company's total assets is 27% lower than its total liabilities
CLSD's quick ratio has plunged by 51% YoY and by 24% from the previous quarter
The current ratio has contracted by 50% YoY and by 23% from the previous quarter
CLSD's equity has dropped by 169% year-on-year and by 158% since the previous quarter
The debt to equity has soared by 59% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.